DNA DNA Plc

DNA Plc’s Financial Statements Bulletin 2019

DNA Plc’s Financial Statements Bulletin 2019

DNA’s net sales and EBITDA reach record levels in 2019, driven by strong mobile service revenue

DNA PLC STOCK EXCHANGE RELEASE 28 JANUARY 2020, 8:30 AM EET

This is a summary DNA’s Financial Statements Bulletin 2019. The complete report is attached to this release and also available at .

Summary

Unless otherwise stated, the comparison figures in brackets refer to the corresponding period in the previous year (reference period). Figures are unaudited. The impact of IFRS 16 on the statement of financial position and income statement is presented in Note 12.

In December 2019, due to redemption of minority shares in DNA by Telenor Finland Holding oy, DNA has applied for the termination of public trading in DNA's shares and for delisting of DNA's shares from the official list of Nasdaq Helsinki. The trading in DNA shares will be terminated after Telenor has obtained title to all outstanding shares in DNA.

October–December 2019



  • Net sales increased 2.3% and amounted to EUR 242.4 million (236.9 million).
  • Mobile service revenue grew 6.6% and was EUR 123.6 million (116.0 million).
  • EBITDA increased 10.7% and was EUR 72.4 million (65.4 million), or 29.9% (27.6%) of net sales.
  • The comparability of the operating result in the reference period was affected by a non-recurring expense item of EUR 3.1 million.
  • The operating result decreased 8.4% and was EUR 26.1 million (28.4 million). The operating result as a percentage of net sales was 10.8% (12.0%).
  • The comparable operating result increased 2.6% and came to EUR 29.2 million (28.4 million).
  • IFRS 16 had a positive effect on EBITDA in the quarter and an insignificant impact on the operating result (Note 12).
  • Earnings per share was EUR 0.14 (0.16).
  • Revenue per user (ARPU) for mobile communications decreased 0.6% and was EUR 18.7 (18.9).
  • The mobile communication subscription turnover rate (churn) increased and was 17.5% (14.8%).
  • In December, DNA applied to delist its shares from the official list of Nasdaq Helsinki.

January–December 2019

  • Net sales increased 3.3% and amounted to EUR 942.1 million (911.8 million).
  • Mobile service revenue grew 7.0% and was EUR 486.4 million (454.4 million).
  • EBITDA increased 7.2% and was EUR 305.6 million (284.9 million), or 32.4% (31.2%) of net sales.
  • Comparable EBITDA increased 8.8% and came to EUR 309.9 million (284.9 million).
  • In the review period, the comparability of EBITDA was affected by non-recurring expense items of EUR 4.3 million in relation to business restructuring.
  • The comparability of the operating result was affected by non-recurring items of EUR 7.4 million.
  • The operating result decreased 3.7% and was EUR 133.7 million (138.9 million). The operating result as a percentage of net sales was 14.2% (15.2%).
  • The comparable operating result increased 1.6% and came to EUR 141.1 million (138.9 million).
  • IFRS 16 had a positive effect on EBITDA in the review period and an insignificant impact on the operating result (Note 12).
  • Operating free cash flow increased 12.3% and was EUR 169.6 million (151.0 million).
  • Earnings per share was EUR 0.75 (0.77).
  • The mobile communication subscription base shrank 1.9%, totalling 2,822,000 (2,877,000).
  • Revenue per user (ARPU) for mobile communications remained constant at EUR 18.7 (18.7).
  • The mobile communication subscription turnover rate (churn) also remained constant at 16.2% (16.2%).
  • The fixed-network subscription base (voice, broadband, and cable television) grew 7.7% to 1,241,000 subscriptions (1,152,000).
  • At the time of the publication of the Financial Statements Bulletin, DNA’s Board of Directors has not made a decision on a proposal to the Annual General Meeting on the possible distribution of a dividend per share.

DNA’s guidance for 2020

DNA has changed the way it issues guidance on future outlook, and it will not issue guidance on its net sales and EBITDA for 2020. DNA expects competition to remain strong in 2020. Nonetheless, DNA’s business is anticipated to develop favourably. DNA’s financial position and liquidity are expected to remain at a healthy level.



Key figures

Figures are unaudited.

EUR million 10–12/2019 10–12/2018 Change (%) 1–12/2019 1–12/2018 Change (%)
Net sales 242.4 236.9 2.3 942.1 911.8 3.3
EBITDA 72.4 65.4 10.7 305.6 284.9 7.2
% of net sales 29.9 27.6   32.4 31.2  
Comparable EBITDA 72.4 65.4 10.7 309.9 284.9 8.8
% of net sales 29.9 27.6   32.9 31.2  
Depreciation, amortisation, and impairment 46.3 37.0   171.9 146.0  
Operating result, EBIT 26.1 28.4 –8.4 133.7 138.9 –3.7
% of net sales 10.8 12.0   14.2 15.2  
Comparable operating result 29.2 28.4 2.6 141.1 138.9 1.6
% of net sales 12.0 12.0   15.0 15.2  
Net result before tax 24.0 26.3 –8.7 124.6 127.7 –2.4
Net result for the period 19.0 21.2 –10.4 98.8 102.2 –3.3
Return on investment (ROI), % 9.3 11.5   12.1 14.1  
Return on equity (ROE), % 13.9 14.2   17.1 16.4  
Capital expenditure 74.2 53.7 38.1 158.7 138.3 14.8
Cash flow after investing activities  3.3 10.5 –68.5  60.6 63.4 –4.6
Free cash flow to equity       88.5 72.0  
Net debt - -   559.1 379.3  
Net debt/EBITDA 1.93 1.45   1.83 1.33  
Net gearing, % - -   101.4 62.7  
Equity ratio, % - -   38.8 46.9  
Basic earnings per share, EUR 0.14 0.16   0.75 0.77  
Diluted earnings per share, EUR 0.14 0.16   0.75 0.77  
Personnel at end of period - -   1,624 1,590  

CEO’s review

Once again, DNA has fared well in a challenging market environment. Net sales for January–December increased 3.3% and amounted to EUR 942.1 million. The positive development was fuelled in particular by our mobile service revenue, which grew 7.0%, and by robust mobile device sales, which were up 10.3%. Comparable EBITDA developed strongly in 2019, reflecting growth from both business segments. Comparable EBITDA grew 8.8% from the reference period to EUR 309.9 million, or 32.9% of net sales.

Competition intensified further during the last quarter of the year. Even so, both our growth and profitability showed a positive trend. Net sales increased 2.3% year-on-year and amounted to EUR 242.4 million. Positive net sales development was fuelled in particular by strong mobile service revenue, which grew 6.6% from the last quarter of 2018, boosted by favourable development of our customer billing and postpaid subscription base. Mobile device sales were up 3.2%. Comparable EBITDA improved 10.7% in the last quarter and was EUR 72.4 million, or 29.9% of net sales.

Our mobile communication subscription base decreased by 55,000 in the October–December period, due to a decrease in prepaid subscriptions. Our postpaid subscription base increased by 37,000. Revenue per user (ARPU) decreased slightly from the reference period to EUR 18.7, due to a decrease in interconnection charges from the reference period. Our customer churn rate was 17.5%. Our fixed-network subscription base grew by 89,000, boosted by new broadband connections in particular.

We are in the process of launching the sales of 5G subscriptions to consumer and corporate customers. In early 2020, DNA’s 5G network will be available in more than 20 locales. Customers using 5G subscriptions benefit from higher speeds and lower latency. The benefits of 5G and its positive impact on customer experience will become more evident as customers use increasingly rich content, higher resolution videos, and services such as online gaming, where low latency is critical. In December, we launched the sales of our 5G Fixed Wireless Access service. The solution provides super-fast connections in areas where fibre-optic connections are not available or would be very expensive to build. We will continue to improve and expand our 4G network parallel to the 5G investments.

In August, Norwegian telecommunications group Telenor acquired a 54% stake in DNA and became the main shareholder. After the completion of the transaction and the resulting mandatory public tender offer, Telenor’s holding of DNA shares was 97.87%. Telenor then commenced mandatory redemption proceedings for the remaining shares, following which DNA submitted an application to Nasdaq Helsinki in December, requesting the termination of public trading in DNA’s shares and the delisting of DNA’s shares from the official list of Nasdaq Helsinki. Delisting of DNA share is possible once Telenor has the right to obtain title to all DNA’s minority shares, which is expected to take place in early 2020.

We will continue the long-term development of our business, focusing on customer experience, personnel satisfaction, and the resulting profitable growth. We expect our business to develop favourably in 2020.

Jukka Leinonen

CEO

Additional information:

Jukka Leinonen, CEO, DNA Plc, 0,

Timo Karppinen, CFO, DNA Plc, 7,

Marja Mäkinen, Head of IR, DNA Plc, 2,

DNA Corporate Communications, 0,

DNA is one of the leading telecommunications companies in Finland. We want to make our customers' daily lives less complicated. We offer connections, services and devices for homes and workplaces, contributing to the digitalisation of society. DNA’s mobile communication network customers have the highest mobile data usage per subscription in the world. We are Finland's largest cable TV operator. DNA has more than 4 million subscriptions in its fixed and mobile communications networks. The company was ranked the best employer in Finland in the large companies’ category of the 2019 Great Place to Work survey. In 2019, our net sales were EUR 942,1 million and we employ about 1,600 people around Finland. DNA is a part of Telenor Group, the leading ICT company in the Nordics. Additional information: , Twitter @DNA_fi, Facebook @DNA.fi and LinkedIn.

 

Attachment

EN
28/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DNA Plc

 PRESS RELEASE

DNA Plc: Changes in DNA's financial reporting

DNA Plc: Changes in DNA's financial reporting DNA PLC STOCK EXCHANGE RELEASE 13 March 2020, 15:00 pm EETDNA changes its financial reporting from the beginning of 2020. The company publishes half year (January-June) financial report and Financial statements bulletin for 2020 financial period. For the January-March and January-September periods DNA publishes Business reviews including CEO's review and certain financial and operative key figures as press release. DNA's financial report in 2020:16 July 2020: Half year (January-June) 2020 financial report DNA's Business reviews in ...

 PRESS RELEASE

DNA Oyj: Muutos DNA:n taloudellisessa raportoinnissa

DNA Oyj: Muutos DNA:n taloudellisessa raportoinnissa DNA OYJ PÖRSSITIEDOTE 13.3.2020 klo 15.00 DNA muuttaa taloudellista raportointiaan vuoden 2020 alusta alkaen. Yhtiö julkistaa puolivuotiskatsauksen (tammi-kesäkuulta) ja koko tilikaudelta. Tammi-maaliskuulta ja tammi-syyskuulta DNA julkistaa lehdistötiedotteella liiketoimintakatsauksen sisältäen toimitusjohtajan katsauksen sekä keskeiset taloudelliset ja operatiiviset avainluvut. DNA:n taloudellisen raportin julkistus vuonna 2020:16.7.2020: Puolivuotiskatsaus, tammi-kesäkuu 2020 DNA:n liiketoimintakatsauksen julkistukset vuo...

Peter Kurt Nielsen
  • Peter Kurt Nielsen

DNA - Terminating coverage

ABGSC ceases coverage of DNA SELL is our final recommendation EUR 20.9 is our final target price

 PRESS RELEASE

DNA Plc’s Annual Report including Board of Directors' Report and Fin...

DNA Plc’s Annual Report including Board of Directors' Report and Financial Statements for 2019 is published DNA PLC STOCK EXCHANGE RELEASE 28 February 2020, 11:00 EET  DNA’s Annual Report 2019 was published today on 28 February 2020 on company's website:   Annual Report includes the Board of Directors Report and the Financial Statements consisting of the Consolidated Financial Statements and the Parent Company Financial Statements. DNA’s Annual Report includes also a Corporate Governance Statement for 2019. In addition, DNA’s Annual Report includes Corporate Responsibility Report prepar...

 PRESS RELEASE

DNA Oyj:n vuosikertomus sisältäen hallituksen toimintakertomuksen ja...

DNA Oyj:n vuosikertomus sisältäen hallituksen toimintakertomuksen ja tilinpäätöksen vuodelta 2019 on julkaistu DNA OYJ PÖRSSITIEDOTE 28.2.2020 KLO 11.00  DNA julkaisi tänään vuoden 2019 vuosikertomuksensa osoitteessa:    Vuosikertomus sisältää hallituksen toimintakertomuksen ja virallisen tilinpäätöksen, johon kuuluu konsernitilinpäätös ja emoyhtiön tilinpäätös. Lisäksi DNA julkaisi vuosikertomuksen yhteydessä selvityksen hallinto- ja ohjausjärjestelmästä vuodelta 2019. Vuosikertomus sisältää myös GRI-standardien (Global Reporting Initiative 2016) mukaisesti laaditun vastuullisuusrapor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch